Oxcarbazepine

🧮 Dose calculator

Epilepsy (complex partial / absence seizures) · Regimen source: FDA Oxcarbazepine · 2.1FDA Oxcarbazepine · 2

• • Adjunct: target 1,200 mg/day. Conversion to monotherapy: target 2,400 mg/day. CrCl <30: start 300 mg/day. FDA Oxcarbazepine · 2FDA Oxcarbazepine · 2.7

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Oxcarbazepine · 8.1

  “Risk Summary Although oxcarbazepine tablets is closely related structurally to carbamazepine, which is considered to be teratogenic in humans, available human data from published literature and ongoing pregnancy registry studies on use of oxcarbazepine during pregnancy have not demonstrated an increased prevalence of …”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Oxcarbazepine · 8.2

  “Risk Summary Oxcarbazepine and its active metabolite (MHD) are present in human milk after oxcarbazepine tablets administration.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Oxcarbazepine · 8.4

  “The safety and effectiveness for use as adjunctive therapy for partial-onset seizures in pediatric patients below the age of 2 have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Oxcarbazepine · 8.5

  “Close monitoring of sodium levels is required in elderly patients at risk for hyponatremia [see Warnings and Precautions (5.1) ] .”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Oxcarbazepine · 8.3

  “Contraception Use of oxcarbazepine tablets with hormonal contraceptives containing ethinylestradiol or levonorgestrel is associated with decreased plasma concentrations of these hormones and may result in a failure of the therapeutic effect of the oral contraceptive drug.”